Invest in

Drug-Patent Cliffs


Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for as low as $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
Open a Motif account to view and trade this basket of stocks:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 0.8%
21.4% Taro Pharmaceutical Industries Ltd. TARO 1.0%
18.9% Abbott Laboratories ABT 33.0%
17.1% The Medicines Company MDCO 4.5%
16.3% 8xx 8xxxxxx 8xxxxxxxxxxx 8xx 8xx 88.8%
7.8% 8xxx 8xxxxxxxxxxxxx 8xxxxxxxxx 8xxxxxx 8 8xxx 88.8%
6.9% 8xxx 8xxxxxxxxxxxx 8xx 8xxx 88.8%
6.8% 8xxxx 8xxx 8xx 88.8%
3.4% 8xxxxxxxxxxx 8xx 8xx 88.8%
1.3% 8xxxxxx 8xxxxxxxxxx 8xx 88.8%

Quotes delayed 15 mins. Currently Jul 16, 2018 2:31:41 PM. Fields are marked with -- when data is unavailable.